“Valuation and risks to price target achievement. We reiterate our Buy rating and $11 price target. Our valuation is based on our clinical net present value (NPV) model, which is currently driven by the company’s two lead assets, CK-301 and CK-101. This model allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Factors which could impede reaching our price target include failed or inconclusive clinical trials or inability of the company to secure adequate funding to progress its drugs through the development pathway.”
According to TipRanks.com, Pantginis has 0 stars on 0-5 star ranking scale with an average return of -16.0% and a 28.4% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Iovance Biotherapeutics Inc, and Dova Pharmaceuticals Inc.
Currently, the analyst consensus on Checkpoint Therapeutics Inc is a Moderate Buy with an average price target of $11.
Based on Checkpoint Therapeutics Inc’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $9.34 million. In comparison, last year the company had a GAAP net loss of $5.92 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Checkpoint Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializes in the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers.